Physician profile
Dmitriy M Niyazov
NPI 1699950899
$330,923.67
in general payments reported to CMS, 2019-2025
11 companies · $62K in 2025
The $62K reported for 2025 was more than what 96% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $13K · 2021: $29K · 2022: $80K · 2023: $49K · 2024: $77K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $153K · Travel and Lodging: $21K · Consulting Fee: $9,169 · Food and Beverage: $3,804 · Honoraria: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $152,859.00 |
| Travel and Lodging | $20,961.44 |
| Consulting Fee | $9,168.74 |
| Food and Beverage | $3,803.78 |
| Honoraria | $1,980.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $199,590.38 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $116,183.96 | 2019-2025 | Strensiq |
| Sarepta Therapeutics, INC. | $6,846.53 | 2025 | |
| Amicus Therapeutics, INC. | $4,468.97 | 2021-2022 | |
| Zevra Therapeutics INC | $1,680.00 | 2025 | Olpruva |
| Biomarin Pharmaceutical INC. | $1,368.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $393.17 | 2019 | |
| Chiesi USA, INC. | $300.00 | 2025 | Elfabrio |
| Jazz Pharmaceuticals INC. | $44.51 | 2022 | |
| Travere Therapeutics, INC. | $28.47 | 2019 | |
| Kyowa Kirin, INC. | $18.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Niyazov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.